Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

New Genzyme pill will cost patients $310,250 a year

By Robert Weisman , Globe Staff

The drug from the Cambridge biotech treats Gaucher disease, a rare genetic disorder.

Ariad shrinks size of footprint in Kendall Sq.

By Robert Weisman , Globe Staff

The cancer drug maker will sublease 170,000 square feet of space at the site that will become its new headquarters.

Alkermes submits application for schizophrenia drug

By Robert Weisman , Globe Staff

Alkermes plc, a Dublin-based biotech with executive offices in Waltham, has asked US regulators to approve its experimental treatment for schizophrenia.

Biopharmaceutical companies shifting labs, jobs to Mass.

By Robert Weisman , Globe Staff

Amid an industry push to tighten and refocus, research and development jobs in the state have only increased.